TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32883108

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 35158135

Group type: EXPERIMENTAL
Intervention: Serious game simulation (SGS) based training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (traditional training)
Number of subjects: 90
Study: 32785614

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27342
Study: 35385557

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.2 mg before general anesthesia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 38
Study: 33253662

Group type: EXPERIMENTAL
Intervention: Older cohort (IIH patients >50 years)
Number of subjects: 65
Study: 32154632

Group type: EXPERIMENTAL
Intervention: 'disorder‐first' language
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: 'person‐first' language
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: 'victim' language
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: 'recovery' language
Number of subjects: 361
Study: 34839863

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 110
Study: 33108123

Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JX) pill (12 g/d, 6 g twice a day) for 4 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (12 g/d, 6 g twice a day) for 4 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JX) pill
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 33905053

Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program, a 30-week mentoring and skills group preventive intervention
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 426
Study: 34537675

Group type: EXPERIMENTAL
Intervention: Prognostic model including residual cancer burden index
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Risk stratification model
Number of subjects: 749
Study: 33084560

Group type: EXPERIMENTAL
Intervention: Emergency medical services (EMS) handovers
Number of subjects: 79
Study: 35422171

Group type: EXPERIMENTAL
Intervention: High-Frequency TENS (80-120 HZ, Intensity 15-30 amp, Pulse duration 250 Micro sec, 60 min per session)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-Frequency TENS (1-5 HZ, Intensity 30-80 amp, Pulse duration 250 Micro sec, 60 min per session)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine medical care and dressing (Control)
Number of subjects: 60
Study: 34868518

Group type: EXPERIMENTAL
Intervention: Lidocaine combined with dexmedetomidine group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single lidocaine group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single dexmedetomidine group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 34753557

Group type: EXPERIMENTAL
Intervention: RAS blockers (monotherapy or dual blockade)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels > 4.84 pg/mL
Number of subjects: 70

Group type: COMPARATOR
Intervention: RAS blockade (monotherapy or dual blockade)
Number of subjects: 70
Study: 33600437

Group type: EXPERIMENTAL
Intervention: Intraplexus injection of 25mL ropivacaine 0.5% between C5‐C6 nerve roots
Number of subjects: 208

Group type: COMPARATOR
Intervention: Extraplexus injection of 25mL ropivacaine 0.5% anterior and posterior to the brachial plexus
Number of subjects: 208
Study: 34081058

Group type: EXPERIMENTAL
Intervention: Sprint training (SPR) including 12 × 30‐s maximal sprints during five LIT sessions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CON) performing distance‐matched LIT only
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sprint training (SPR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neither group
Number of subjects: 18
Study: 33757975

Group type: EXPERIMENTAL
Intervention: Information portal (intervention group)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 343
Study: 33243209

Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg/morning and 3 mg/at bedtime (Group IIIb)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (Group IIIa)
Number of subjects: 152
Study: 33933267

Group type: EXPERIMENTAL
Intervention: PEEK abutments (20 titanium‐supported PEEK abutments)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zirconia abutments (20 zirconia abutments)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control teeth (contralateral teeth)
Number of subjects: 40
Study: 32899069

Group type: EXPERIMENTAL
Intervention: Acupuncture method of removing-stasis and resuscitating
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 50
Study: 34969889

Group type: EXPERIMENTAL
Intervention: Loss-based incentivization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Streak incentivization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FitBit-received flat-rate incentivization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monetary flat-rate incentivization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic incentivization (combined loss-based and streak)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat-rate incentivization (combined FitBit and monetary)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall symptom resolution
Number of subjects: 30
Study: 33713924

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation in childhood
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation in childhood
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Nutritional supplementation and psychosocial stimulation interaction
Number of subjects: 1268
Study: 33029267

Group type: EXPERIMENTAL
Intervention: 2 ml methylene blue
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3.5 ml methylene blue
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 ml methylene blue
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3 ml methylene blue
Number of subjects: 15
Study: 35568804

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with clopidogrel plus aspirin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Baseline clinical factors (carotid stenosis or occlusion, cohort type, race, baseline statin use, systolic blood pressure, serum glucose, age)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 181
Study: 34248110

Group type: EXPERIMENTAL
Intervention: Higher-level functional capacity (HLFC)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Lower social role in men
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Lower IADL and intellectual activity in women
Number of subjects: 1824
Study: 32105092

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms with all variables
Number of subjects: 3869

Group type: EXPERIMENTAL
Intervention: Multiple logistic regressions with all variables
Number of subjects: 3869

Group type: EXPERIMENTAL
Intervention: Univariate logistic regressions
Number of subjects: 3869

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms after removing top 5 variables
Number of subjects: 3869
Study: 35580972

Group type: EXPERIMENTAL
Intervention: Lung recruitment
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 234
Study: 33551196

Group type: EXPERIMENTAL
Intervention: Dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 18
Study: 32175587

Group type: EXPERIMENTAL
Intervention: Educational materials provided at the start of aviation training (intervention group)
Number of subjects: 851

Group type: COMPARATOR
Intervention: No educational materials provided (control group)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Survey responders in the intervention group who previously reported non-vaccine use
Number of subjects: 851
Study: 36460184

Group type: EXPERIMENTAL
Intervention: SibChat intervention (8 sessions of 60 minutes each via video conference)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 83
Study: 33754705

Group type: EXPERIMENTAL
Intervention: Lysophosphatidic acids (LPAs) measurement in COPD patients
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy donor sera
Number of subjects: 200
Study: 33227131

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right dorsolateral prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 34210347

Group type: EXPERIMENTAL
Intervention: Combined tDCS and VR-based therapy (30 minutes each)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined tDCS and VR-based therapy
Number of subjects: 29
Study: 36190145

Group type: EXPERIMENTAL
Intervention: Two short implants (6 mm) with single-unit restorations (group TWO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: One single short implant (6 mm) with a cantilever restoration (group ONE-C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (group ONE-C and group TWO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group ONE-C
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group TWO
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Implants that survived
Number of subjects: 36
Study: 34077539

Group type: EXPERIMENTAL
Intervention: FDA-required nicotine warning
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: 100 cigarettes warning
Number of subjects: 1152
Study: 32653248

Group type: EXPERIMENTAL
Intervention: Exercise-based injury prevention program (IPP) for 8 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal cricket activity (Control)
Number of subjects: 8
Study: 36034130

Group type: EXPERIMENTAL
Intervention: Yijinjing Qigong Exercise (YJJQE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine segmental rehabilitation training)
Number of subjects: 60
Study: 32112126

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block, continuous sciatic nerve block and single‐shot obturator nerve block (group R)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Local infiltration analgesia and a continuous intraarticular catheter with ropivacaine (group L)
Number of subjects: 140
Study: 35756982

Group type: EXPERIMENTAL
Intervention: Intraneural facilitation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 10
Study: 35237863

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34119909

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 157
Study: 32474816

Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study: 35858154

Group type: EXPERIMENTAL
Intervention: Oral Paclitaxel plus Encequidar (oPac + E) 205 mg/m2 paclitaxel plus 15 mg E, 3 consecutive days per week
Number of subjects: 402

Group type: COMPARATOR
Intervention: Intravenous Paclitaxel (IVpac) 175 mg/m2 once every 3 weeks
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Oral Paclitaxel plus Encequidar (oPac + E)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Intravenous Paclitaxel (IVpac)
Number of subjects: 402
Study: 32959110

Group type: EXPERIMENTAL
Intervention: 75 mg of ASA administered in the evening (n = 56)
Number of subjects: 114

Group type: COMPARATOR
Intervention: 75 mg of ASA administered in the morning (n = 58)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (n = 61) - patients with arterial hypertension but without coronary heart disease, not receiving ASA
Number of subjects: 114
Study: 32957353

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS in M1 area on the contralateral side and 3 Hz rTMS at Neiguan and Sanyinjiao points
Number of subjects: 42

Group type: COMPARATOR
Intervention: Acupuncture (body acupuncture)
Number of subjects: 42
Study: 36038163

Group type: EXPERIMENTAL
Intervention: Lobe-specific lymph node dissection (L-SLND)
Number of subjects: 1344

Group type: COMPARATOR
Intervention: Systematic lymph node dissection (SLND)
Number of subjects: 1344
Study: 34964825

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection (US)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Freehand injection (FH)
Number of subjects: 117
Study: 35221930

Group type: EXPERIMENTAL
Intervention: Cortico–peripheral Hebbian-type stimulation (HTS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 90
Study: 32046718

Group type: EXPERIMENTAL
Intervention: Generic artemether-lumefantrine (Artefan®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Innovator artemether-lumefantrine (Coartem®)
Number of subjects: 0
Study: 34379539

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 126

Group type: COMPARATOR
Intervention: Not given chewing gum (Control)
Number of subjects: 126
Study: 32649717

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous hydromorphone (IVH)
Number of subjects: 82
Study: 36115273

Group type: EXPERIMENTAL
Intervention: White individual
Number of subjects: 1833

Group type: COMPARATOR
Intervention: White female
Number of subjects: 1833

Group type: COMPARATOR
Intervention: Black male
Number of subjects: 1833

Group type: EXPERIMENTAL
Intervention: Male individual transitioning to heroin
Number of subjects: 1833
Study: 32333876

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 458

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 458
Study: 35564858

Group type: EXPERIMENTAL
Intervention: High-Intensity Circuit Resistance Exercise (HCRE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (activities of daily living)
Number of subjects: 30
Study: 34227949

Group type: EXPERIMENTAL
Intervention: Targeted client communication intervention using text messages, tailored to pregnant and postpartum women, developed through co-design and theory-based approaches.
Number of subjects: 26
Study: 32700798

Group type: EXPERIMENTAL
Intervention: S-Praziquantel (S-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-Praziquantel (R-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Number of subjects: 0
Study: 35412448

Group type: EXPERIMENTAL
Intervention: Dry needling plus upper cervical spinal manipulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Interocclusal splint therapy, diclofenac, and TMJ mobilization
Number of subjects: 120
Study: 33494639

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intervention designed to obliterate the AVM
Number of subjects: 0
Study: 32997684

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) intervention providing danger sign messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) intervention providing family planning messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 0
Study: 35840960

Group type: EXPERIMENTAL
Intervention: Training programme for Pharmacist Independent Prescribers (PIPs) including two training days, professional development planning, mentor support, and a viva with an independent GP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training programme for Pharmacist Independent Prescribers (PIPs)
Number of subjects: 25
Study: 34967368

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham laser acupuncture (C)
Number of subjects: 180
Study: 34557930

Group type: EXPERIMENTAL
Intervention: [68 Ga]Ga‐P16‐093
Number of subjects: 20
Study: 33682970

Group type: EXPERIMENTAL
Intervention: Real high‐efficiency particulate air filter (HEPA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham high‐efficiency particulate air filter (HEPA)
Number of subjects: 54
Study: 32568867

Group type: COMPARATOR
Intervention: Entecavir monotherapy (n = 70)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Entecavir add-on peg-interferon therapy (n = 74)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups (monotherapy and combination therapy)
Number of subjects: 144
Study: 35653637

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 2146
Study: 33748055

Group type: EXPERIMENTAL
Intervention: ESRα promoter methylation levels
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Triglyceride (TG)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL‐C)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Lower methylation levels (≤4.07%)
Number of subjects: 1143
Study: 32017167

Group type: EXPERIMENTAL
Intervention: 6-month supplementation with carnitines and other micronutrients
Number of subjects: 104
Study: 35804307

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (cisplatin and 5-fluorouracil plus radiotherapy followed by surgical resection)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Any observed increase in CTCs
Number of subjects: 96
Study: 34916645

Group type: EXPERIMENTAL
Intervention: Non-surgical peri-implantitis treatment combined with systemic antimicrobials
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full mouth non-surgical peri-implantitis treatment
Number of subjects: 60
Study: 35560305

Group type: EXPERIMENTAL
Intervention: High Sodium (HS) diet (6,900 mg/day) with Placebo (PL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Sodium (HS) diet (6,900 mg/day) with Antioxidants (AO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low Sodium (LS) diet (2,300 mg/day) with Placebo (PL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low Sodium (LS) diet (2,300 mg/day) with Antioxidants (AO)
Number of subjects: 10
Study: 34438029

Group type: EXPERIMENTAL
Intervention: SZL (3.2 g/d)
Number of subjects: 156

Group type: COMPARATOR
Intervention: FLX (20 mg/d)
Number of subjects: 156
Study: 35119243

Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 32857944

Group type: EXPERIMENTAL
Intervention: Spinal thrust manipulation and electrical dry needling (TMEDN group)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonthrust peripheral joint/soft tissue mobilization, exercise, and interferential current (NTMEX group)
Number of subjects: 145
Study: 34737549

Group type: EXPERIMENTAL
Intervention: 2% Hyaluronic Acid (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 36293787

Group type: EXPERIMENTAL
Intervention: Individual lifestyle coaching
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Group lifestyle coaching
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group for individual coaching
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group for group coaching
Number of subjects: 319
Study: 34918639

Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate capsules (220 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin capsules (200 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bismuth pectin granules (150 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bismuth pectin granules (300 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 240
Study: 35589494

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) during walking exercise (60% arterial occlusion pressure)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Walking exercise without Blood Flow Restriction (Control)
Number of subjects: 16
Study: 32563609

Group type: EXPERIMENTAL
Intervention: Low-dosage sIPV
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Medium-dosage sIPV
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High-dosage sIPV
Number of subjects: 240

Group type: COMPARATOR
Intervention: Salk IPV (reference)
Number of subjects: 240
Study: 34783875

Group type: EXPERIMENTAL
Intervention: SoC + noncontrast CT
Number of subjects: 862

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 862
Study: 33770374

Group type: EXPERIMENTAL
Intervention: 1mm PSF reconstruction
Number of subjects: 46

Group type: COMPARATOR
Intervention: EARL-compliant reconstruction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard reconstruction
Number of subjects: 46
Study: 32105353

Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 1635
Study: 36304071

Group type: EXPERIMENTAL
Intervention: iNPWT for 14 postoperative days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 20
Study: 36437131

Group type: EXPERIMENTAL
Intervention: Interactive robot during postoperative mobilization
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care during mobilization
Number of subjects: 84
Study: 33414503

Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0